Insulet Corp. logo
PODDInsulet Corp.

Average Return on Equity (ROE)

Return on Equity (ROE)

The latest reported return on equity (roe) is 16.31% as of Wednesday, December 31, 2025, shown against its trailing averages.

PODD Return on Equity (ROE)

PODD Average Return on Equity (ROE)

PODD Return on Equity (ROE) Averages

RETURN ON EQUITY (ROE) LATEST REPORTED

16.31%

RETURN ON EQUITY (ROE) TTM

25.41%

RETURN ON EQUITY (ROE) 3Y

19.99%

RETURN ON EQUITY (ROE) 5Y

14.02%

RETURN ON EQUITY (ROE) 10Y

-16.15%

RETURN ON EQUITY (ROE) 15Y

-23.27%

RETURN ON EQUITY (ROE) 20Y

-35.27%

About Insulet Corp.

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Acton, MA
5,400 employees
Healthcare / Medical - Devices
Sector
Healthcare
Industry
Medical - Devices
CEO
Ashley A. McEvoy